Introduction
The proto-oncoprotein c-Cbl is involved in the regulation of signaling initiated by several different receptor types and acts principally as a negative regulator of signal transduction (Liu and Altman, 1998; . c-Cbl is a complex adapter with multiple, diverse, protein interaction domains ( Figure 1 ). The structure of c-Cbl includes a tyrosine kinase binding (TKB) domain, a RING finger domain, which confers ubiquitin E3 ligase activity and recruits E2 ubiquitin-conjugating enzymes, numerous potential SH3 and SH2 domain-binding motifs, as well as an ubiquitin-associated domain and a leucine zipper (Lupher et al., 1999; ). Accumulating evidence indicates that c-Cbl negatively regulates signaling by growth factor receptors by mediating the multiubiquitination and degradation of the receptors (Sawasdikosol et al., 2000) . c-Cbl has also been demonstrated to negatively regulate the activation of the nonreceptor protein tyrosine kinase, Syk, and that of phospholipase Cg1 (PLCg1) (Ota and Samelson, 1997; Graham et al., 2000) .
PLCg1 catalyzes the hydrolysis of phosphatidylinositol (4,5)-bisphosphate to inositol (1,4,5)-trisphosphate and diacylglycerol, which control calcium mobilization and protein kinase C activation, respectively (Rhee and Bae, 1997) . In T cells, the PLCg1-regulated Ca 2 þ mobilization controls Ca 2 þ -dependent transcriptional events that govern cellular responses, such as cytokine production (Wange and Samelson, 1996) . T-cell receptor (TCR)-induced PLCg1 activation is controlled by nonreceptor protein tyrosine kinases, including Lck and Zap-70 (Williams et al., 1998 (Williams et al., , 1999 Kane et al., 2000) , the phosphorylation of the adapters Lat and Slp-76 (Yablonski et al., 1998; Zhang et al., 1999a, b) , and the tyrosine phosphorylation of PLCg1 itself (Todderud et al., 1990; Kim et al., 1991) .
The mechanism by which c-Cbl regulates PLCg1 activation is unknown, but some clues may be inferred from the effects of c-Cbl mutants. We have previously reported that, contrary to wild-type c-Cbl that inhibits antigen receptor-induced PLCg1 activation and PLCg1/ Ca 2 þ -dependent transcriptional events (Graham et al., 2000; Yasuda et al., 2000) , ectopic expression of an oncogenic form of c-Cbl, the 70Z/3 Cbl mutant, leads to augmented basal and TCR-induced PLCg1 signaling (Graham et al., 2000) . 70Z/3 Cbl and WT Cbl differ in a 17-amino acid deletion in 70Z/3 Cbl (aa 366-382) that abrogates E3 ubiquitin-ligase activity ( Figure 1 ) (Sawasdikosol et al., 2000) , suggesting that the E3 function is required for c-Cbl to negatively regulate PLCg1. It is also possible that the signaling and oncogenic activity of 70Z/3 Cbl requires its ability to dimerize with endogenous c-Cbl via the C-terminal leucine zipper, resulting in blockade of the physiologic inhibitory function of c-Cbl (Bartkiewicz et al., 1999; van Leeuwen et al., 1999a, b) .
To understand the mechanism of 70Z/3 Cbl signaling, we compared the structural and molecular requirements of TCR-and 70Z/3 Cbl-induced PLCg1 activation. We demonstrate here that 70Z/3 Cbl induces the activation of the PLCg1/Ca 2 þ pathway by a mechanism that is characterized by a distinct usage of PLCg1 src-homology (SH) interaction domains. This 70Z/3 Cbl-mediated PLCg1 activation is dependent upon the Zap-70 kinase as well as the TKB and C-terminal regions of 70Z/3 Cbl, but is independent of the Zap-70 substrates, Slp-76 and Lat. These results are consistent with a model in which 70Z/3 Cbl forms a TCR-independent molecular complex that bypasses Lat and Slp-76 in the activation of PLCg1.
Results
The carboxyl-terminal region of 70Z/3 c-Cbl is required for the enhancement of basal and TCR-induced PLCg1 tyrosine phosphorylation
The oncogenic c-Cbl variant 70Z/3 Cbl has been shown to induce the phosphorylation and activation of PLCg1 (Graham et al., 2000) . To gain insight into the potential mechanism, we first examined the effect of 70Z/3 Cbl on the kinetics of TCR-induced PLCg1 phosphorylation. Jurkat T cells, cotransfected with WT PLCg1-HA and 70Z/3 Cbl or a vector control (pCI-neo), were left unstimulated or stimulated for the indicated times with the anti-TCR antibody C305. 70Z/3 Cbl expression augmented both basal and TCR-induced PLCg1 phosphorylation at all time points (Figure 2a Cbl had no effect on the kinetics of TCR-induced phosphorylation of PLCg1 or its dephosphorylation ( Figure 2b) .
Next, we compared the effect of 70Z/3 Cbl to that of c/v-Cbl, an oncogenic truncated form of c-Cbl, which encompasses amino acids 1-357 (Figure 1 ). While expression of 70Z/3 Cbl resulted in increased basal and TCR-induced PLCg1 tyrosine phosphorylation, expression of c/v-Cbl as well as overexpression of WT c-Cbl did not affect PLCg1 phosphorylation (Figure 3a) . These data indicate that the ability to affect PLCg1 signaling does not directly correlate with the transforming ability of c-Cbl variants and suggest that amino acids 358-906 are essential for 70Z/3 Cbl-induced PLCg1 activation.
We then analysed the ability of carboxyl-terminal truncation mutants of 70Z/3 Cbl to induce PLCg1 phosphorylation. 70Z/3 Cbl deletion constructs 1-840 70Z/3 Cbl and 1-730 70Z/3 Cbl were expressed at lower levels than WT 70Z/3 Cbl (Figure 3b , bottom panel), making a side-by-side comparison with the full-length construct and other mutants difficult. Both constructs, however, were able to augment PLCg1 phosphorylation in both unstimulated and TCR-stimulated cells, albeit to a lower level than that seen with WT 70Z/3 Cbl ( Figure 3b ). It is unclear as to whether the diminished ability of 1-840 and 1-730 70Z/3 Cbl to phosphorylate PLCg1 was because of their lower expression level or deletion of a region that is involved in PLCg1 phosphorylation. The fact that they did retain the ability to augment PLCg1 phosphorylation, however, suggests that the regions deleted from these constructs, in particular the leucine zipper region between amino acids 857-895, are not absolutely required for the ability of 70Z/3 Cbl to augment PLCg1 phosphorylation. Deletion of all major tyrosine phosphorylation sites plus most of the proline-rich region (1-558 70Z/3 Cbl) diminished, but did not eliminate, the effect of 70Z/3 Cbl on PLCg1 phosphorylation, which was completely abrogated only when all potential SH3 and SH2 domain-binding motifs had been deleted (1-480 70Z/3 Cbl). These data indicate that 70Z/3 Cbl-induced PLCg1 signaling cannot be solely explained by inhibition of endogenous c-Cbl through dimerization via the leucine zipper and that the interaction of 70Z/3 Cbl with the SH3 and/or SH2 domains of other proteins plays an important role.
TCR-induced PLCg1 tyrosine phosphorylation and the effect of 70Z/3 Cbl have distinct PLCg1 structural requirements PLCg1 contains two SH2 domains and one SH3 domain. We have previously established that TCRinduced PLCg1 tyrosine phosphorylation is predominantly dependent upon an intact N-terminal SH2 (SH2N) domain and independent of the C-terminal SH2 (SH2C) domain Since it has previously been established that TCR-induced PLCg1 phosphorylation requires the interaction of the PLCg1 SH2N domain with phospho-Lat Zhang et al., 1998 Zhang et al., , 2000 , we examined whether pp36-38/Lat was required for 70Z/3 Cbl-induced PLCg1 phosphorylation. Our results indicate that we can detect augmented basal ( In contrast to WT PLCg1 and the SH2N domain mutant of PLCg1, both basal and TCR-induced phosphorylation of the SH2C, the SH2N/C, or the SH3 domain mutants of PLCg1 were unaffected or only marginally increased by 70Z/3 Cbl expression ( Figure 5 ). Therefore the SH2C and SH3 domains of PLCg1 play a role in both the induction of basal phosphorylation and the enhancement of TCR-induced PLCg1 phosphorylation by 70Z/3 Cbl. These data indicate that the effect of 70Z/3 Cbl on the phosphorylation of PLCg1 has unique PLCg1 subdomain requirements compared with TCRinduced PLCg1 phosphorylation and provide the first evidence for an SH2N domain-independent and SH2C/ SH3 domain-dependent phosphorylation of PLCg1 in T cells.
The seven C-terminal tyrosine phosphorylation sites of Cbl are not required for the effect of 70Z/3 Cbl on PLCg1 tyrosine phosphorylation
To address whether 70Z/3 Cbl tyrosine phosphorylation is required for its effect on PLCg1 phosphorylation, we The enhancement of basal and TCR-induced PLCg1 phosphorylation by 70Z/3 Cbl requires the SH2C and SH3 domains of PLCg1. Jurkat T cells were cotransfected with the indicated HA-tagged PLCg1 constructs along with either untagged 70Z/3 Cbl or pCI-neo. Cells and anti-HA immunoprecipitates were treated as in Figure 3a utilized a 70Z/3 Cbl mutant (7X 70Z/3 Cbl) in which the seven C-terminal tyrosine residues of 70Z/3 Cbl that represent all the known tyrosine phosphorylation sites of c-Cbl have been mutated. Although the 7X 70Z/3 Cbl mutant shows no detectable tyrosine phosphorylation either constitutively or in response to TCR cross-linking (van Leeuwen et al., 1999a, b) , it did induce similar levels of PLCg1 phosphorylation compared to WT 70Z/3 Cbl (Figure 6a and b) . These data suggest that an interaction mediated by any of these tyrosine residues with the SH2 domains of other proteins, including PLCg1 SH2 domains, is not required for the effect of 70Z/3 Cbl on PLCg1 phosphorylation. Whether other minor tyrosine phosphorylation sites play a role remains to be established.
70Z/3 Cbl-induced NFAT activation is independent of PTEN in Jurkat cells and occurs in SupT1 cells
Previous studies have established a role for the Tec kinases in the phosphorylation and activation of PLCg1 (Schaeffer and Schwartzber, 2000) . The activation of certain Tec kinases is regulated by their recruitment to the plasma membrane via an interaction of their pleckstrin homology domain with membrane D3-phosphorylated phosphoinositides, whose level is negatively regulated by the phosphatase PTEN. Since Jurkat T cells lack PTEN, there is a constitutive high amount of D3-phosphoinositides, which results in a constitutive membrane localization of the Tec kinase Itk (Shan et al., 2000) . To determine if the lack of PTEN expression plays a role in 70Z/3 Cbl-induced PLCg1 activation, we reconstituted PTEN expression together with 70Z/3 Cbl in Jurkat T cells and assessed the induction of the nuclear factor of activated T cells (NFAT)-dependent transcriptional activation, an event downstream of PLCg1 in the PLCg1-dependent Ca 2 þ activation pathway. An inactive form of PTEN, PTEN C/S, was used as a control. The activity of PTEN was confirmed by the degree of reduction in constitutive phosphorylation of the serine/threonine kinase Akt on Ser 473 by phosphospecific immunoblot assay (Figure 7a ). PTEN reconstitution in Jurkat cells, however, did not decrease 70Z/3 Cbl-induced NFAT activation (Figure 7b ), indicating that 70Z/3 Cbl-induced activation of the PLCg/Ca 2 þ pathway in Jurkat T cells is independent of PTEN expression.
To further confirm that the activation of PLCg1 by 70Z/3 Cbl is not unique to Jurkat T cells, we compared it to that of another T cell line, SupT1, which expresses PTEN (data not shown). Jurkat and SupT1 cells were transiently transfected with the NFAT-luciferase construct along with pCI-neo or 70Z/3 Cbl. As for Jurkat T cells, 70Z/3 Cbl expression led to a constitutive NFAT activation in SupT1 cells of substantial magnitude (Figure 7c ). To determine if 70Z/3 Cbl also affects PLCg1 phosphorylation in these cells, SupT1 cells were transfected with WT PLCg1-HA, and either pCI-neo or 70Z/3 Cbl. The results indicate that, as is the case for Jurkat cells, 70Z/3 Cbl expression leads to constitutive PLCg1 phosphorylation in SupT1 cells (Figure 7c ).
The effect of 70Z/3 Cbl on PLCg1 phosphorylation requires Zap-70
Since the Zap-70 kinase is required for TCR-induced PLCg1 phosphorylation and activation, we sought to ascertain the role of Zap-70 in the effect of 70Z/3 Cbl on PLCg1 phosphorylation. Since Zap-70 interacts with the TKB domain of Cbl (Fournel et al., 1996; Lupher et al., 1996 Lupher et al., , 1997 , we utilized a 70Z/3 Cbl TKB domain mutant (G306E 70Z/3 Cbl, Figure 1 ). At levels of expression equivalent to those of 70Z/3 Cbl, G306E 70Z/3 Cbl was unable to induce PLCg1 phosphorylation (Figure 6a and b) , indicating that an intact TKB domain is required for the effect of 70Z/3 Cbl on PLCg1 phosphorylation.
Additional evidence for a Zap-70 requirement in the effect of 70Z/3Cbl on PLCg1 phosphorylation was obtained by expressing WT PLCg1-HA together with either 70Z/3 Cbl or pCI-neo in the Zap-70-deficient Jurkat cell line P116 (Williams et al., 1998) , and comparing the effect to that observed in P116 cells stably reconstituted with Zap-70. At equivalent levels of 70Z/3 Cbl expression, no PLCg1 phosphorylation was detected in either unstimulated or TCR-triggered P116 
70Z/3 Cbl-induced NFAT activation requires Zap-70 but is independent of Slp-76
Slp-76, a Zap-70 substrate, is an adapter protein that is required for PLCg1 phosphorylation and activation in T cells (Yablonski et al., 1998) . It was therefore of interest to compare 70Z/3 Cbl-induced NFAT activation in Zap-70-or Slp-76-deficient Jurkat cell lines. Deficient cells and cells reconstituted with the corresponding molecule as controls were cotransfected with 70Z/3 Cbl or pCI-neo and an NFAT-luciferase reporter construct. As previously reported (van Leeuwen et al., 1999a, b) , Zap-70 was required for 70Z/3 Cbl-induced NFAT activity (Figure 9a) . Surprisingly, expression of 70Z/3 Cbl led to constitutive NFAT activity in Slp-76-deficient cells (Figure 9b ). The fact that 70Z/3 Cbl expression can lead to a decrease in NFAT activation in TCRstimulated cells has been previously reported, but the reason for the decrease remains unclear (Zhang et al., 1999a, b) . Consistent with the lack of a requirement for Slp-76 in NFAT activation, we observed comparable levels of 70Z/3 Cbl-induced PLCg1 phosphorylation in Slp-76-deficient and reconstituted cells (Figure 9c ).
Discussion
We and others have previously established that 70Z/3 Cbl can induce activation of both the Ras and PLCg1 pathways in T cells (van Leeuwen et al., 1999a, b; Graham et al., 2000) . In this study, we demonstrate that, compared to the unique requirement for the SH2N domain in TCR-induced phosphorylation, the effect of 70Z/3 Cbl on PLCg1 phosphorylation requires both SH2 domains and the SH3 domain of PLCg1. Furthermore, 70Z/3 Cbl can exploit a signaling mechanism distinct from that used by the TCR, resulting in PLCg1 activation in a manner that is independent of Lat and Slp-76.
During TCR signaling, Lat, once phosphorylated, acts as a scaffold that recruits PLCg1 via a direct interaction with the SH2N domain of PLCg1 and indirectly via a ternary complex involving phospho-Lat binding to Gads, an interaction of Gads with Slp-76 Boerth et al., 2000) , and a constitutive interaction of Slp-76 with the SH3 domain of PLCg1 (Yablonski et al., 2001) . Slp-76 plays a role in TCR-induced PLCg1 activation (Yablonski et al., 1998) , possibly by recruiting the Tec kinase Itk (Su et al., 1999) . In the case of 70Z/3 Cbl, our data strongly suggest that PLCg1 phosphorylation and activation results from the assembly of an alternate complex between PLCg1 and 70Z/3 Cbl, mediated by the interaction of the SH3 domain of PLCg1 with the proline-rich region of 70Z/3 Cbl. First, we have shown here that the proline-rich region of 70Z/3 Cbl is critical in mediating the effect of 70Z/3 Cbl on PLCg1 phosphorylation, since c/v-Cbl and the truncated 1-480 70Z/3 Cbl were without effect. Furthermore, PLCg1 and 70Z/3 Cbl interact in T cells in a constitutive manner (data not shown), consistent with our previous finding that c-Cbl is constitutively bound to the SH3 domain of PLCg1 . In addition, in the presence of 70Z/3 Cbl, PLCg1 phosphorylation can occur in the absence of detectable coprecipitating phospho-Lat or a functional SH2N domain, the crucial structure that mediates the direct interaction of PLCg1 with phosphorylated Lat in TCRinduced signaling. Lastly, the induction of PLCg1 activation by 70Z/3 Cbl, as measured by PLCg1 phosphorylation and NFAT transcriptional induction, is independent of Slp-76. Our data suggest that 70Z/3 Cbl substitutes for Slp-76 and the interaction with phospho-Lat in the activation of PLCg1 by promoting or itself nucleating an alternate complex with signaling properties similar to those of the complex formed by Lat/Gads/Slp-76 with PLCg1. Interestingly, in addition to Slp-76, Itk has been shown to bind c-Cbl (Bunnell et al., 1996) , a property that is likely to be shared by 70Z/3 Cbl. 70Z/3 Cbl differs from c-Cbl only in a 17-amino acid deletion that disrupts the linker a-helix and the RING finger domain, structures that contribute to the E3 ubiquitin-ligase activity of c-Cbl (Joazeiro et al., 1999; Sawasdikosol et al., 2000; Zheng et al., 2000) . Our findings with 70Z/3 Cbl, therefore, may also reveal a function physiologically carried out by c-Cbl. We speculate that, similarly to 70Z/3 Cbl, c-Cbl may also enucleate a signaling complex that incorporates an SH3 domain-dependent interaction with PLCg1. Upon signaling by certain receptors, the functional RING/Ubligase domain in c-Cbl mediates the ubiquitination of proteins within this complex and subsequent signal downregulation. Consistent with this hypothesis, we have found that c-Cbl overexpression in T cells þ Jurkat) were cotransfected with HA-tagged WT PLCg1 and untagged 70Z/3 Cbl or pCI-neo. Cells and anti-HA immunoprecipitates were treated as in Figure 3a . Expression of HA-tagged PLCg1 in different cell lines was confirmed by stripping the membrane and probing with anti-HA. 70Z/3 Cbl expression was determined by immunoblotting whole-cell lysates with anti-Cbl negatively regulates TCR-induced PLCg1 activation, albeit it did not affect PLCg1 phosphorylation (Graham et al., 2000) . Therefore, c-Cbl may function in T cells by sequestering PLCg1 from a productive Lat and Slp-76 activation complex and hence negatively regulate PLC activation. There are also examples, such as the c-Met receptor and the interleukin 4 receptor signaling pathways, where c-Cbl positively regulates signal transduction (for a complete review see Tsygankov et al., 2001) , suggesting that c-Cbl can, under specific conditions, enucleate a productive activation complex.
Interestingly, reconstitution of PLCg1-deficient Jurkat cells with an SH3 domain-negative mutant of PLCg1 was shown to induce increased transcriptional activity in T cells (Irvin et al., 2000) , suggesting that this domain interacts with a negative regulatory protein, such as cCbl. If Slp-76 also interacts with PLCg1 SH3 domain (Yablonski et al., 2001) , however, this observation stands in conflict with the positive role of Slp-76 in PLCg1 regulation (Yablonski et al., 1998) , in that an SH3 domain-negative PLCg1 mutant would be expected to be deficient in activation potential. The apparent discrepancy between these reports can be explained on two different grounds. First, Slp-76 is recruited to Lat via Gads and is likely to contribute to a TCR-induced complex and PLCg1 activation independently of binding to PLCg1. Therefore, cells expressing an SH3 domainnegative PLCg1 mutant do not recapitulate the signaling defect of cells lacking Slp-76. Second, the apparent increase in interleukin 2 transcription observed in cells expressing an SH3 domain-negative mutant of PLCg1 after TCR aggregation in combination with PMA was mitigated by a concomitant increase observed in the same cells treated with PMA and ionomycin (Irvin et al., 2000) . Therefore, the inhibitory effect of the SH3 domain on transcription is exerted in large part downstream or independently of Ca 2 þ mobilization and protein kinase C activation. Notably, in Jurkat cells we have observed levels of TCR-induced phosphorylation of the SH3 domain-negative PLCg1 mutant comparable to those of wild-type PLCg1 ( Figure 5 ). This observation suggests that the interaction of the PLCg1 SH3 domain with Slp-76 is not crucial for TCRinduced PLCg1 phosphorylation and is consistent with the SH2N domain of PLCg1 as being the critical structure for TCR-induced recruitment of PLCg1 to the Lat scaffold.
It has been suggested that cell activation by 70Z/3 Cbl can be explained by a direct blockade of endogenous cCbl through heterodimerization (Bartkiewicz et al., 1999; van Leeuwen et al., 1999a, b) . Our data show that removal of the C-terminal leucine zipper did not eliminate the effect of 70Z/3 Cbl on PLCg1 phosphorylation, suggesting that the formation of 70Z/3 Cbl/cCbl heterodimers cannot be the sole basis for the activating potential of 70Z/3 Cbl. Complete abrogation of PLCg1 phosphorylation was only obtained with the elimination of the proline-rich region and all potential SH3 domain-binding sites, consistent with 70Z/3 Cbl binding the SH3 domain of PLCg1. Whether the activating potential of 70Z/3 Cbl completely resides in its inability to ubiquitinate proteins or also results in sequestration of proteins from c-Cbl remains to be determined. In support of multiple mechanisms, recent evidence suggests that the inability of 70Z/3 Cbl to mediate the multiubiquitination and degradation of growth-factor receptors is not the sole basis for its transforming abilities .
The C-terminal tyrosine residues of c-Cbl are phosphorylated in response to TCR ligation and mediate interactions with known signaling molecules, including Vav, the p85 subunit of PI3K, and the Crk proteins. A 70Z/3 Cbl mutant lacking all seven corresponding tyrosine phosphorylation sites induced PLCg1 phosphorylation, suggesting that interactions mediated by these residues are not required for 70Z/3 Cbl-induced PLCg1 phosphorylation. In contrast, both SH2 domains of PLCg1 play a role in 70Z/3 Cbl-induced PLCg1 phosphorylation, possibly by mediating the association of PLCg1 with additional minor tyrosine phosphorylated sites of 70Z/3 Cbl or with, as yet, other undefined molecules.
Zap-70 and its interaction with the TKB domain of 70Z/3 Cbl were required for 70Z/3 Cbl-induced signaling via PLCg1. Since Zap-70 is also required for TCRinduced PLCg1 phosphorylation (Williams et al., 1998 (Williams et al., , 1999 , one can speculate that Zap-70 itself is responsible for the phosphorylation of PLCg1. PLCg1, however, does not appear to be a direct substrate of Zap-70 (Veri et al., 2001) and no increase in Zap-70 phosphorylation or kinase activity has been observed in Jurkat cells expressing 70Z/3 Cbl (van Leeuwen et al., 1999a, b; Zhang et al., 1999a, b) , making it unlikely that 70Z/3 Cbl alters the kinase activity of Zap-70. We favor the hypothesis that Zap-70 is required for events other than direct PLCg1 phosphorylation. This includes the possibility that Zap-70 may function upstream of other kinases required for PLCg1 activation, including Itk (Shan and Wange, 1999) , or as an adapter that mediates the translocation of 70Z/3 Cbl to the proximity of the TCR (Neumeister et al., 1995) , favoring the association of 70Z/3 Cbl with other regulatory proteins.
Does 70Z/3 Cbl-induced PLCg activation play a role in the transformation process? PLCg1 overexpression has been associated with transformation in NIH 3T3 and 3YL fibroblasts (Chang et al., 1997; Smith et al., 1998) and PLCg1 expression and activity are elevated in several human tumors (Johnson et al., 1994; Noh, 1994; Lee et al., 1995) . It should also be noted that 70Z/3 Cblinduced in vitro transformation is quantitatively and qualitatively more pronounced than that observed with c/v-Cbl (Andoniou et al., 1994) . This observation suggests that 70Z/3 Cbl and c/v-Cbl may have different mechanisms of transformation and is consistent with the unique ability of 70Z/3 Cbl to activate signaling pathways in the absence of external stimuli, including its ability to stimulate PLCg1. While additional studies will be necessary to determine the role of PLCg1 activation in 70Z/3 Cbl-induced cell transformation, this report provides the first evidence that 70Z/3 Cbl induction of PLCg1 activation proceeds via an alternate mechanism that is independent of receptorproximal events required for ligand-induced signal transduction.
Materials and methods

Cell lines and reagents
SupT1 and Jurkat cell lines were maintained in RPMI 1640 supplemented with 7.5% FCS. A CD3-high Jurkat T-cell line was as previously described (Rellahan et al., 1997) . The Zap-70 negative (P116) and reconstituted cell lines were from Dr RT Abraham (Duke University, Durham, NC, USA) (Williams et al., 1998) . The Slp-76 deficient (J14-v-29) and reconstituted (J14-76-11) clones as well as the anti-TCR antibody C305 were from Dr A Weiss (UCSF, San Francisco, CA, USA) (Yablonski et al., 1998) . The anti-hemagglutinin (HA) antibody 12CA5 was a gift from A Weissman (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA). The anti-HA antibody 3F10 was from Boehringer Mannheim (Indianapolis, IN, USA). The antiphosphotyrosine antibody 4G10 was from Upstate Biotechnology (Lake Placid, NY, USA). The anti-Cbl antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the phopho-Akt (Ser 473) antibody was from Cell Signaling Technology (Beverley, MA, USA), and the anti-PTEN antibody was from Cascade Biosciences (Winchester, MA, USA).
DNA plasmids and transfections
The assembly of Cbl and 70Z/3 Cbl in pCI-neo (pCI-Cbl, pCI-70Z/3) has been previously described (Rellahan et al., 1997; Graham et al., 2000) . The HA-tagged c/v-Cbl and 70Z/3 Cbl in pJZEN/Neo was a gift from Dr W Langdon (University of Western Australia, Australia). c/v-Cbl-HA in pCI-neo was generated in the same manner as previously described for nontagged c/v-Cbl (Rellahan et al., 1997) . To generate HAtagged 70Z/3 Cbl in pCI-neo (pCI-70Z/3 Cbl HA), BamHI was used to shuttle 70Z/3 Cbl from pJZEN/Neo into pGEM11Zf þ . Sal I was used to excise 70Z/3 from pGEM-11Zf þ and clone into pCI-neo. The assembly of HA-tagged bovine PLCg1 in pCI-neo (WT PLCg1(HA)) and the site-directed mutagenesis of the SH2N, SH2C, and SH3 domains have also been previously described DeBell et al., 1999) . The G306E, 7X (Y674F, Y700F, Y731F, Y735F, Y774F, Y869F, Y871F), and 1-840 mutants of 70Z/3 Cbl in pSX were a gift from Dr L Samelson (Laboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA) (van Leeuwen et al., 1999a, b) . To generate the G306E, 7X, and 1-840 mutants in pCI-neo, a Blp I site in 70Z/3 Cbl was utilized. The G306E and 7X mutants were cloned into non-HA tagged pCI-70Z/3 Cbl and the 1-840 mutant into pCI-70Z/3 Cbl HA. Sequences corresponding to amino acids 1-730, 1-558, 1-528, and 1-480 of 70Z/3 Cbl were amplified by PCR and cloned into the pCI-70Z/3 Cbl HA vector by using a 5 0 Blp I site and a 3 0 Not I site encoded by the lower PCR primer. The pSRa-Flag-PTEN and pSRa-Flag-PTEN C124S (PTEN C/S) were as described previously (Shan et al., 2000) . All transfections were performed by electroporation with the indicated amounts of DNA as previously described (Rellahan et al., 1994) .
Cell activation, immunoprecipitation, and Western blot analysis
For TCR stimulation, cells were activated with the anti-TCR antibody C305 for 2 min at 371C unless otherwise indicated. Cells were lysed as previously described . Postnuclear lysates were precipitated with the anti-HA antibody 3F10 bound to Protein A/G beads (Pierce, Rockford, IL, USA). Proteins were eluted with sample buffer, resolved by SDS-PAGE, and transferred to nitrocellulose membranes (Hybond-C Super; Amersham, Arlington Heights, IL, USA). Protein detection was with the indicated antibodies followed by appropriate second antibody, and either [ 125 I] Protein A (ICN, Costa Mesa, CA, USA or NEN, Boston, MA, USA) or Western Lightning Chemiluminescence Reagent Plus (PerkinElmer, Boston, MA, USA). When necessary, blots were stripped according to the membrane manufacturer's directions and reprobed immunoblots were scanned on a Phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA) or a FluorChemt 8800 Imaging System (Alpha Innotech Corp., San Leandro, CA, USA) and analysed with ImageQuant software (Molecular Dynamics).
NFAT luciferase assays
The indicated constructs were cotransfected with a plasmid containing a luciferase reporter under the control of the interleukin 2 minimal promoter and three optimized NFAT enhancer elements (a gift of Dr G Crabtree, Stanford, CA, USA). At 24 h after transfection, cells were incubated with medium alone, C305, or 10 ng/ml PMA plus 1 mm ionomycin for an additional 5 h. Cells were lysed and assayed using the Luciferase Assay System from Promega (Madison, WN, USA). Data are expressed as the percentage of maximum activation with PMA plus ionomycin.
Abbreviations BCR, B-cell receptor; TCR, T-cell receptor; PLCg1, phospholipase Cg1; SH, src-homology; TKB, tyrosine kinase binding; EGF, epidermal growth factor.
